Rasagiline Teva (Rasagiline)

What Is Rasagiline Teva and What Is It Used For?

Rasagiline Teva belongs to a class of medications known as monoamine oxidase type B (MAO-B) inhibitors. It is specifically approved for the treatment of idiopathic Parkinson's disease in adult patients. The medication can be prescribed as a standalone treatment (monotherapy) for patients in the early stages of Parkinson's disease, or as an add-on therapy alongside levodopa for patients with more advanced disease who experience motor fluctuations.

Teva Pharmaceutical Industries, headquartered in Israel, originally synthesised and developed rasagiline. The molecule was first authorised in the European Union in 2005 and by the U.S. Food and Drug Administration (FDA) in 2006 under the brand name Azilect. Following patent expiry, rasagiline became available from multiple manufacturers, but Teva continues to market the product as Rasagiline Teva (and Azilect in many regions). All formulations contain the same active substance and are therapeutically equivalent.

Parkinson's disease is a progressive neurodegenerative disorder characterised by the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. Dopamine is a critical neurotransmitter involved in coordinating smooth, purposeful movement. As dopamine levels decline, patients develop the hallmark symptoms of Parkinson's disease: resting tremor, muscle rigidity, bradykinesia (slowness of movement), and postural instability. According to the World Health Organization (WHO), Parkinson's disease affects more than 8.5 million people globally and remains the second most common neurodegenerative disorder after Alzheimer's disease.

Rasagiline addresses this dopamine deficiency by selectively and irreversibly inhibiting the MAO-B enzyme in the brain. MAO-B is responsible for a significant portion of dopamine metabolism in the central nervous system. By blocking this enzyme, rasagiline slows the enzymatic breakdown of dopamine, effectively increasing and sustaining dopamine levels in the striatum. This pharmacological action helps compensate for the reduced dopamine production that characterises Parkinson's disease.

When used as monotherapy, rasagiline provides modest but clinically meaningful improvements in motor function. The TEMPO and ADAGIO clinical trials demonstrated that rasagiline monotherapy significantly improved UPDRS (Unified Parkinson's Disease Rating Scale) motor scores compared to placebo. When used as adjunctive therapy with levodopa, rasagiline reduces "off" time (periods when Parkinson's symptoms return between medication doses) by approximately 0.5 to 1 hour per day, as demonstrated in the PRESTO and LARGO trials. These pivotal trials — many sponsored by Teva as the originator — underpin the worldwide regulatory approval of rasagiline.

What Should You Know Before Taking Rasagiline Teva?

Contraindications

There are several important situations in which rasagiline must not be used. Understanding these contraindications is essential for safe treatment and is listed clearly in both the European Medicines Agency (EMA) Summary of Product Characteristics and the U.S. FDA prescribing information.

If you have been taking rasagiline and need to start an MAO inhibitor or pethidine, you must wait at least 14 days after your last dose of rasagiline. This washout period is critical because rasagiline irreversibly inhibits MAO-B, and the body needs time to synthesise new MAO-B enzyme before it is safe to introduce another MAO-active drug. Failure to observe this washout period could result in dangerous interactions, including hypertensive crisis or serotonin syndrome.

Warnings and Precautions

Several important precautions should be discussed with your healthcare provider before and during treatment with rasagiline.

Liver problems: If you have mild to moderate liver impairment, your doctor will need to carefully consider whether rasagiline is appropriate for you. The medication is metabolised primarily by the liver enzyme CYP1A2, and reduced liver function may lead to increased drug exposure. Rasagiline is contraindicated in patients with severe hepatic impairment.

Skin cancer risk: Treatment with rasagiline may potentially increase the risk of melanoma (skin cancer). This association has been observed in epidemiological studies, although it is unclear whether this is related to the medication itself, Parkinson's disease, or other confounding factors. Patients on rasagiline should have regular dermatological examinations and should report any new or suspicious skin changes to their doctor promptly. Both EMA and FDA labelling include this precaution.

Impulse control disorders: Rasagiline, like other dopaminergic medications used in Parkinson's disease, may cause impulse control disorders. These are behavioural changes where patients cannot resist the urge to perform certain activities that could be harmful. Reported impulse control disorders include pathological gambling, compulsive shopping or spending, binge eating, compulsive sexual behaviour, and an abnormally high sex drive. If you or your family members notice any such behavioural changes, contact your healthcare provider immediately, as dose adjustment or treatment discontinuation may be necessary.

Drowsiness and sudden sleep onset: Rasagiline may cause somnolence (excessive daytime sleepiness) and episodes of suddenly falling asleep during daily activities. This risk is particularly elevated when rasagiline is combined with other dopaminergic medications. Patients should exercise caution when driving or operating machinery, especially during the initial treatment period and any time the dose of concomitant dopaminergic therapy is adjusted.

Hypertensive episodes: Although rasagiline is selective for MAO-B at the recommended dose, post-marketing reports include rare cases of elevated blood pressure (including severe hypertensive episodes) following ingestion of large quantities of tyramine-rich food. Patients should be alert for symptoms such as severe headache, visual disturbances, chest pain, or shortness of breath, and seek medical attention if these occur.

Pregnancy and Breastfeeding

The safety of rasagiline during pregnancy has not been established in clinical studies. Animal studies are insufficient to fully assess reproductive toxicity. Because the potential risk to the developing fetus is unknown, rasagiline should be avoided during pregnancy unless the potential benefit clearly outweighs the possible risk. Women of childbearing potential should discuss appropriate contraceptive measures with their healthcare provider.

It is not known whether rasagiline or its metabolites are excreted in human breast milk. Experimental data suggest rasagiline may inhibit prolactin secretion and consequently lactation. Given the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue rasagiline therapy, taking into account the importance of the medication to the mother. Consult your doctor for personalised advice.

Children and Adolescents

Rasagiline is not indicated for use in children and adolescents under 18 years of age. Parkinson's disease is exceedingly rare in this population, and the safety and efficacy of rasagiline have not been studied in pediatric patients. There is no relevant use of rasagiline in the pediatric population for its approved indication.

How Does Rasagiline Teva Interact with Other Drugs?

Drug interactions with rasagiline can be clinically significant and potentially dangerous. The mechanism of action of rasagiline as an MAO-B inhibitor means it interacts with the serotonergic and adrenergic systems, creating the potential for serious pharmacodynamic interactions with a range of medications. Always inform your doctor or pharmacist about all medications you are taking, including over-the-counter products and herbal supplements.

Major Interactions (Contraindicated or Avoid)

Moderate Interactions (Use with Caution)

Serotonin syndrome is a potentially life-threatening condition that can occur when serotonergic medications are combined with MAO inhibitors. Symptoms include agitation, confusion, rapid heart rate, elevated blood pressure, dilated pupils, muscle twitching, tremor, hyperthermia, and sweating. If you experience any combination of these symptoms while taking rasagiline, seek immediate medical attention.

What Is the Correct Dosage of Rasagiline Teva?

Adults

Unlike some Parkinson's medications, rasagiline does not require dose titration. The starting dose is the maintenance dose. Clinical trials have shown that 1 mg once daily provides optimal efficacy without increasing the risk of adverse effects compared to lower doses. In the TEMPO trial, 2 mg daily did not provide additional benefit over 1 mg and was associated with more side effects.

Elderly Patients

No dose adjustment is required for elderly patients. Rasagiline has been extensively studied in older adults, as Parkinson's disease predominantly affects this population. The pharmacokinetics of rasagiline are not significantly altered by age. However, elderly patients may be more susceptible to orthostatic hypotension and should be monitored accordingly, particularly during the initial weeks of treatment.

Hepatic Impairment

Patients with mild hepatic impairment should use rasagiline with caution, as drug metabolism may be reduced. Rasagiline is contraindicated in patients with severe hepatic impairment. For moderate hepatic impairment, the decision to use rasagiline should be made on an individual basis by the treating physician, weighing the benefits against the risks of increased drug exposure. If hepatic function deteriorates from mild to moderate during treatment, rasagiline should be discontinued.

Renal Impairment

No dose adjustment is required in patients with renal impairment. The major metabolite, 1-aminoindan, is not an MAO inhibitor and does not appear to accumulate clinically significantly even in renal dysfunction.

Children

Rasagiline is not indicated for use in children or adolescents under 18 years of age. There are no clinical data to support its use in this population.

Missed Dose

If you forget to take your daily dose of rasagiline, do not take a double dose to make up for the missed one. Simply take the next dose at the usual scheduled time. Because rasagiline irreversibly inhibits MAO-B, a single missed dose is unlikely to cause a significant return of symptoms, as the enzyme inhibition persists until new MAO-B is synthesised (typically over approximately 14 days).

Overdose

Symptoms reported following rasagiline overdose include mild euphoria (a mild form of mania), extremely elevated blood pressure, and serotonin syndrome. Serotonin syndrome symptoms may include agitation, confusion, tremor, rapid heart rate, high body temperature, and excessive sweating. Treatment of overdose is supportive and symptomatic, with monitoring of vital signs and cardiac function. There is no specific antidote for rasagiline overdose.

Stopping Treatment

Do not stop taking rasagiline without first consulting your doctor. While abrupt discontinuation of rasagiline is generally not associated with a withdrawal syndrome (unlike some other dopaminergic medications), stopping therapy may lead to worsening of Parkinson's disease symptoms. Your doctor will advise you on how to manage your treatment plan if discontinuation is necessary.

What Are the Side Effects of Rasagiline Teva?

Like all medicines, rasagiline can cause side effects, although not everyone experiences them. The type and frequency of side effects may differ depending on whether rasagiline is used alone or in combination with levodopa. When used with levodopa, dyskinesia (involuntary movements) is the most commonly reported side effect, as the increased dopamine levels from MAO-B inhibition enhance the effects of levodopa.

If you notice any side effects, including any not listed above, inform your healthcare provider. Reporting suspected adverse reactions after marketing authorisation is important, as it allows ongoing monitoring of the benefit-risk balance of the medicine. You can report side effects to your national health authority (such as the FDA MedWatch programme in the United States or the EMA's EudraVigilance system in Europe) or through your healthcare provider.

It is worth noting that many of these side effects overlap with the symptoms of Parkinson's disease itself. For example, falls, depression, and orthostatic hypotension are common in Parkinson's patients regardless of medication use. Your doctor will help distinguish between disease-related symptoms and medication-related side effects.

Can You Drive While Taking Rasagiline Teva?

Both Parkinson's disease itself and treatment with rasagiline can affect your ability to safely drive a vehicle or operate machinery. Rasagiline may cause dizziness, drowsiness, and in some cases, episodes of suddenly falling asleep during normal daily activities without warning or without feeling drowsy beforehand.

The risk of somnolence and sudden sleep episodes is particularly increased when rasagiline is combined with other dopaminergic medications commonly used in Parkinson's disease, or when patients consume alcohol. If you have experienced somnolence or sudden sleep attacks at any time during rasagiline treatment, you should not drive or operate machinery.

Before starting rasagiline, discuss with your doctor whether you can safely continue driving. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness. Your ability may be affected by the medication's effects and side effects as described throughout this article. If you are uncertain, consult your doctor or pharmacist.

How Should You Store Rasagiline Teva?

Proper storage of rasagiline is important to maintain the medication's efficacy and safety. The tablets should be stored at a temperature not exceeding 25°C (77°F). Keep the medication in its original packaging (blister pack or bottle) to protect it from moisture and light.

If your Rasagiline Teva comes in a bottle, note the in-use shelf life specified by the manufacturer (typically 3 months from first opening). After this period, any remaining tablets should be discarded even if the printed expiration date has not passed. Write the date of first opening on the bottle to help you track this.

Always keep this medication out of the sight and reach of children. Do not use rasagiline after the expiration date (EXP) printed on the carton, blister, or bottle. The expiration date refers to the last day of that month.

Do not dispose of medications via wastewater or household waste. Ask your pharmacist about proper disposal methods for medications that are no longer needed or have expired. Many countries operate medicine take-back programmes through community pharmacies. These measures help protect the environment.

What Does Rasagiline Teva Contain?

Each Rasagiline Teva tablet contains 1 mg of rasagiline, present as the mesilate salt (rasagiline mesilate, equivalent to 1.56 mg of rasagiline mesilate). Rasagiline is the pharmacologically active component responsible for MAO-B inhibition.

The inactive ingredients (excipients) that typically make up the tablet formulation are:

• Mannitol — a sugar alcohol used as a diluent and bulking agent
• Colloidal anhydrous silica — a flow agent that prevents ingredients from clumping
• Maize starch — tablet binder and disintegrant
• Pregelatinised maize starch — acts as a binder and disintegrant to help the tablet dissolve
• Stearic acid — a lubricant that prevents the tablet from sticking to manufacturing equipment
• Talc — an additional lubricant and glidant

Rasagiline Teva tablets are white to off-white, round, flat tablets, typically with marking embossed on the surface (specific markings vary by market and may include "GIL 1" or similar identification). The tablets are commonly available in blister packs of 7, 10, 28, 30, 100, and 112 tablets, or in a high-density polyethylene bottle (with or without a child-resistant cap) containing 30 tablets. Not all pack sizes may be marketed in every country.

If you are allergic to any of these ingredients, do not take Rasagiline Teva and inform your doctor so they can prescribe an alternative rasagiline formulation or a different MAO-B inhibitor. Always consult the patient information leaflet provided with your specific package, as excipient composition may vary slightly between markets and batches.